Peptidomimetic Macrocycles Stabilize p53 Against HDM2 Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers and hyperproliferative diseases often fail to effectively stabilize or enhance the activity of the p53 protein, which is crucial for preventing malignant transformation, due to the negative regulation by HDM2 and HDMX proteins, leading to inadequate apoptosis and cell cycle arrest.
Innovation Solution
Development of p53-based peptidomimetic macrocycles that stabilize the alpha-helical structure of p53, interfering with its interactions with HDM2 and HDMX, thereby inhibiting their regulatory activities and restoring p53 function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If p53 is targeted to inhibit HDM2/HDMX interactions, then anti-cancer activity is improved, but the short half-life and rapid degradation of p53 by HDM2 limit therapeutic effectiveness
Solution Approach 1:
The patent applies preliminary action by pre-stabilizing p53 through intramolecular crosslinking before it can be degraded by HDM2. The crosslinked p53 structure is prepared in advance with enhanced stability, preventing the rapid degradation that normally occurs, thereby extending its functional half-life and improving therapeutic effectiveness
Solution Approach 2:
The patent employs composite materials by creating crosslinked p53 structures where amino acid residues within p53 are covalently bonded to form a more stable composite structure. This crosslinked composite resists proteolytic degradation and maintains its anti-cancer activity longer than native p53
2Strength
If peptidomimetic macrocycles are used to stabilize p53 structure, then binding affinity to HDM2 is improved, but the complexity of macrocycle synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the macrocycle formation into manageable segments - using specific amino acid sequences with defined crosslinking sites. This modular approach allows systematic synthesis and characterization while maintaining high binding affinity to HDM2
Solution Approach 2:
The patent uses parameter changes by systematically varying crosslinking parameters such as crosslinker type, crosslinking position, and crosslinking density to optimize binding affinity while controlling synthesis complexity. This allows identification of optimal parameters that balance affinity and manufacturability
3Stability of the object's composition
If crosslinking is used to stabilize alpha-helical structure, then resistance to proteolytic degradation is improved, but the structural flexibility required for binding may be reduced
Solution Approach 1:
The patent applies local quality by implementing crosslinking at specific localized positions within the p53 structure rather than uniform crosslinking throughout. This selective local crosslinking stabilizes critical regions resistant to degradation while preserving flexibility in other regions necessary for binding to HDM2 and HDMX
Solution Approach 2:
The patent employs dynamics by creating a balanced crosslinked structure that maintains appropriate flexibility. The crosslinks provide stability where needed while allowing dynamic conformational changes in binding regions, enabling the structure to adapt during the binding process to HDM2 and HDMX targets
Data Source
AI summary
The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.